TTB Rejects Vodka Brand Bellion’s Health Claims

Despite the efforts of vodka brand, the spirit does not reduce the damaging effects on one's liver.
Photo courtesy of Bellion Vodka

The Tobacco Tax and Trade Bureau quietly rejected the idea that vodka bottled and distributed by Secaucus, NJ-based Bellion reduced the negative effects of booze on one’s liver. The privately held company claimed in its petition to the TTB that a proprietary blend of three ingredients added to its vodka would lessen alcohol’s effects on the human liver. It sought to add the health claims to its label.

German Discount Supermarket Lidl Invades the South

The blend of glycyrrhizin, mannitol and potassium sorbate was dubbed NTX by its maker, Indian technology company Chigurupati Technologies Private Ltd. Neither company sought to have NTX called a drug, which would have put it under rigorous Federal Drug Administration review. The TTB after conferring with the FDA denied the petition.

Published on June 7, 2017
Topics: Vodka
About the Author
Leslie Gevirtz
Contributing Editor, Business

An award-winning journalist, Gevirtz spent more than 20 years covering disasters—natural, political, and financial—before becoming Reuters’ wine correspondent; a beat that guaranteed her colleagues were always glad to see her.




Want breaking news in the wine world?

Sign up for the Beverage Industry Enthusiast newsletter for a weekly rundown on the latest
Sign up for the
Beverage Industry Enthusiast
newsletter for a weekly
rundawn on the latest
Please enter a valid email address

Welcome to winemag.com! By using our website and/or subscribing to our newsletter, you agree to our use of cookies and the terms of our Privacy Policy